👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Israel to offer fourth COVID vaccine shot to over 60s, medical staff

Published 01/02/2022, 06:15 AM
Updated 01/03/2022, 01:21 AM
© Reuters. A medical worker prepares to give 62-year-old Moshe Geva Rosso a fourth dose of the coronavirus disease (COVID-19) vaccine after Israel's Health Ministry approved a second booster for the immunocompromised, at Sheba Medical Center in Ramat Gan, Israel Dec
PFE
-

By Maayan Lubell

JERUSALEM (Reuters) -Prime Minister Naftali Bennett said on Sunday that Israel would offer a fourth dose of COVID-19 vaccine to people over 60 and to medical staff as it faces a surge in Omicron variant infections.

Israel last week approved a fourth dose of the vaccine developed by Pfizer (NYSE:PFE) and BioNTech, a second booster, for people who are immune-compromised and the elderly living in care homes.

"We now have a new layer of defence," Bennett said in a televised news conference, adding that Israel's top government medical official, whose approval is needed to expand the booster campaign, had signed off on the latest move.

"Israel will once again be pioneering the global vaccination effort," Bennett said.

Earlier, the Health Ministry's Director-General Nachman Ash said Israel could reach herd immunity as Omicron infections mounted and Merck & Co's molnupiravir anti-viral pill was approved for use in COVID-19 patients over 18.

Herd immunity is the point at which a population is protected from a virus, either through vaccination or by people having developed antibodies by contracting the disease.

The highly transmissible Omicron variant has caused a wave of coronavirus cases, with worldwide infections hitting a record high, with an average of just over one million cases detected each day between Dec. 24 and 30, Reuters data showed.

Deaths, however, have not risen to the same degree, raising hopes that the new variant is less lethal, a view Bennett also echoed in describing the second booster as largely a bid to prevent serious illness among the elderly.

Daily cases in Israel are expected to reach record highs in the coming three weeks. Bennett said that up to 50,000 people might soon be infected each day, while eligibility for testing could be tightened to help relieve long lines at testing stations.

"The (infection) numbers will have to be very high in order to reach herd immunity," Ash told 103 FM Radio earlier. "This is possible but we don't want to reach it by means of infections, we want it to happen as a result of many people vaccinating."

The head of the health ministry's coronavirus task force, Salman Zarka, said herd immunity was far from guaranteed, because experience over the past two years showed that some COVID-19 patients who recovered were later reinfected.

Israel's health ministry says around 60% of its 9.4 million population are fully vaccinated, almost all with the Pfizer-BioNTech vaccine, which means they have either received three doses or have recently had their second.

© Reuters. A medical worker prepares to give 62-year-old Moshe Geva Rosso a fourth dose of the coronavirus disease (COVID-19) vaccine after Israel's Health Ministry approved a second booster for the immunocompromised, at Sheba Medical Center in Ramat Gan, Israel December 31, 2021. REUTERS/Nir Elias

But hundreds of thousands of those eligible for a third inoculation have so far not taken it.

Over the past 10 days, daily infections have more than quadrupled. Severe cases have also climbed, but at a far lower rate, rising from about 80 to around 100.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.